Mutation That may Make HIV Drug Resistant Identified

by Medindia Content Team on  December 1, 2007 at 7:14 PM Research News
RSS Email Print This Page Comment
Font : A-A+

Mutation That may Make HIV Drug Resistant Identified
Scientists believe that a mutation in a little-studied structural region of the AIDS virus may be behind resistance to several HIV drugs.

A report published in the open-access journal PLoS Medicine says that several mutations in reverse transcriptase (RT), the viral enzyme that copies the genes of HIV, are already known to cause drug resistance and are routinely detected in blood tests used by doctors to individualize HIV treatment.

The mutation that the scientist suspect to be the cause of HIV drug resistant is called N3481. The report suggests that this mutation is located not in the active part of RT, but rather in the so-called connection domain, which falls outside the region of the virus normally included in resistance tests.

During the study, the researchers analysed the first two-thirds of the RT gene in viruses isolated from more than 1,000 patients in Canada. They found that virus carrying the N348I mutation developed in more than 10 per cent of treatment-experienced patients.

It was observed that patients treated with the HIV drugs zidovudine and nevirapine were 2.6-times more likely to have the N348I mutation than others.

The report states that the mutation appeared early in therapy, often in viruses that had other resistance mutations. It further says that the appearance of the N348I mutation often coincided with an increase in the amount of HIV present in blood.

When the N348I mutation was introduced into HIV growing in the laboratory, the researchers found that it decreased the susceptibility of the virus to drugs, says the report.

Given that the N348I mutation confers resistance to two classes of RT inhibitor drugs and can emerge early during therapy, scientists are now believing that it may have a huge impact on patient responses to antiviral regimens that contain zidovudine and nevirapine.

The report stresses the need to determine whether looking for the N348I mutation may improve the ability of resistance tests to predict treatment outcomes.

Source: ANI
LIN/P

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Related Links

More News on:

Oral Health And AIDS Drug Toxicity AIDS/HIV AIDS/HIV - Epidemiology AIDS/HIV - Clinical Features AIDS/HIV - Health Education AIDS/HIV - Prevention And Transmission AIDS / HIV - Treatment AIDS/HIV- Lab Tests and Faqs Signature Drug Toxicity 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive